Biotech Values

[DewDiligence]

Private company says intravitreal anti-VEGF compound has 6+ months duration—in preclinical models:

https://www.globenewswire.com/news-release/2025/05/07/3075685/0/en/Optigo-Biotherapeutics-Wins-People-s-Choice-Award-at-Eyecelerator-and-Presents-Compelling-Preclinical-Data-on-Long-Acting-Intravitreal-Biologics-at-the-ARVO-2025-Conference.html

…the company presented positive preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, supporting the potential of its proprietary anti-VEGF molecules to achieve dosing intervals of six months or longer in patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

…The company’s proprietary biologics are fusion proteins that combine derisked therapeutics such as aflibercept with an albumin or hyaluronan anchoring domain. In VEGF challenge animal models, these bifunctional molecules demonstrate 2-3x longer half-life compared to aflibercept alone, were not proinflammatory, and were well tolerated with a favorable safety profile.